Sairah Ahmed is an Oncology physician affiliated with The University of Texas MD Anderson Cancer Center. OpenAlex indexes 646 publications with 9,127 citations (h-index 47); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1515 Holcombe Blvd
Houston, TX 770304009
Telephone
713-792-6161Registry record last updated 16 Oct 2012.
Clinical trials
- Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy
Sponsor: Tessa Therapeutics
- Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
Sponsor: Tessa Therapeutics
- Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)
Sponsor: M.D. Anderson Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
21 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year20257 payments$26,168openpaymentsdata.cms.gov ↗
- Celgene CorporationProgram year20256 payments
- ABBVIE INC.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
56.2%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor46.4%Valacyclovir100%Part D≥34 patientsShort-acting sulfonamides9.8%Sulfamethoxazole-Trimethoprim100%Part D<11 patientsMetabolism & gastrointestinal
30.9%Serotonin-3 Receptor Antagonist16%Ondansetron Hcl100%Part D≥23 patientsProton pump inhibitor8.8%Pantoprazole Sodium100%Part D<11 patients+ 1 more class in this area
Nervous system
7.2%Phenothiazine7.2%Prochlorperazine Maleate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome
Biology of Blood and Marrow Transplantation
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”